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hepatorenal syndrome has the worst and parenchymal 
nephropathy – the relatively best prognosis. Prerenal fail-
ure and hepatorenal syndrome are among the most com-
mon causes of renal insufficiency in liver disease. In these 
patients, portal hypertension and splanchnic vasodilata-
tion causes a shift in blood volume away from the central 
circulation. This reduction of centrally effective blood 
volume induces a stimulation of counter-regulatory 
mechanisms such as activation of renin-aldosterone and 
of the sympathetic nervous system. This results in renal 
sodium retention, functional renal failure and ascites for-
mation. Therefore, marked, fast decreases of plasma vol-
ume must be avoided in the treatment of ascites  [1] .
 Large volume paracentesis can induce circulatory dys-
function, resulting in renal failure. Albumin infusion fol-
lowing paracentesis has been impressively shown to re-
duce circulatory dysfunction and to improve survival  [2] . 
Therefore, most guidelines recommend albumin infusion 
following large volume paracentesis in patients with cir-
rhosis. For patients with massive ascites, transjugular in-
trahepatic portosystemic shunt (TIPS) provides good 
control of ascites and reduces the number of paracentesis. 
Moreover, TIPS improves survival in these patients. For 
these beneficial effects, selection of suitable patients is 
crucial. Therefore, patients with serum bilirubin >5 mg/
dl or pre-existing hepatic encephalopathy should not be 
TIPS candidates  [3] .
 Recently, the role of beta-blockers in patients with 
cirrhosis and ascites has been controversially discussed. 
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 Abstract 
 Background: Renal failure in cirrhosis may be due to various 
causes. While treatment for patients with ascites and hepa-
torenal syndrome is established, recent attention has been 
focused on acute kidney injury (AKI) in cirrhosis.  Key Mes-
sages: The reduction of centrally effective blood volume is 
the key to the pathophysiology of renal failure and ascites 
formation in cirrhosis. Therefore, albumin infusion following 
large volume paracentesis is recommended by all guide-
lines. In selected patients, transjugular intrahepatic porto-
systemic shunt provides good control of ascites and im-
proves survival. The role of non-selective beta-blockers in 
patients with cirrhosis and ascites is being controversially 
discussed. AKI in cirrhosis has been redefined and has prog-
nostic importance.  Conclusions: The role of kidney function 
in patients with liver cirrhosis is receiving increasing atten-
tion. In particular, the use of beta-blockers and novel defini-
tions of AKI seem to be of clinical relevance. 
 © 2016 S. Karger AG, Basel 
 In patients with cirrhosis, renal failure can have vari-
ous causes such as parenchymal nephropathy, hypovole-
mia, infection and hepatorenal syndrome. Among those, 
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While beta-blockers reduce portal pressure and there-
fore the risk of variceal bleeding, they also decrease car-
diac output and may impair renal perfusion. A retro-
spective study reported an increase of mortality risk in 
patients with refractory ascites receiving beta-blockers 
 [4] . This was not confirmed by another report  [5] in 
which the patients received a lower mean daily propran-
olol dose than in the afore-mentioned study (49 vs. 113 
mg/day). Untoward effects of beta-blockers may indeed 
be mediated by their effect on mean arterial pressure. 
Patients with spontaneous bacterial peritonitis may be 
particularly prone to develop hypotension when receiv-
ing beta-blockers. This effect has been shown to be 
linked with survival: while patients with spontaneous 
bacterial peritonitis had an increased mortality risk, this 
was not the case in patients undergoing paracentesis 
without spontaneous bacterial peritonitis  [6] . A recent 
prospective study has shown that non-selective beta-
blockers (NSBB) improve survival probability of pa-
tients with ascites on the transplant waiting list  [7] . In-
terestingly, patients receiving Carvedilol had less benefit 
than patients receiving propranolol ( fig. 1 ). This may be 
due to a more marked effect of Carvedilol on systemic 
arterial pressure. Altogether, the use of beta-blockers 
and particularly the dosage should be judiciously esti-
mated, particularly in patients with spontaneous bacte-
rial peritonitis  [8] or patients with low systolic blood 
pressure.
 Hepatorenal syndrome, particularly type I has a detri-
mental prognosis  [9] . Recent studies have shown that ad-







































 Fig. 1. NSBB improve survival of patients 
with ascites on the liver transplantation 
waiting list. The figure shows the cumula-
tive incidence of death over time (adapted 




























 Fig. 2. Survival probability is significantly reduced (p = 0.049) in 
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nal function in patients with hepatorenal syndrome type 
1 and can reduce short-term mortality  [10] . However, 
time to response is rather long and the traditional defini-
tion of hepatorenal syndrome has been questioned as a 
prerequisite for starting innovative treatments. Recently, 
a proposal to broaden the diagnosis of renal dysfunction 
in cirrhosis has been put forward  [11] . It includes cases of 
acute and chronic renal failure not meeting the diagnostic 
criteria of hepatorenal syndrome types 1 and 2, respec-
tively. Rather acute kidney injury (AKI), similarly as in 
patients without cirrhosis should include all causes of 
acute deterioration of renal function as indicated by an 
increase of serum creatinine by >50% from baseline or a 
rise of  ≥ 0.3 mg/dl within few days. Such renal dysfunction 
is a defining feature of acute-on-chronic liver failure  [12] . 
Interestingly, patients characterized by such minor renal 
dysfunction over time exhibit a continuous increase of 
serum creatinine and a decrease of mean arterial pressure 
 [13] . Consequently, mortality risk has been shown in-
creased in these patients ( fig. 2 ). Based on such observa-
tions, the International Club of Ascites has established 
new definitions for the diagnosis and management of 
AKI in patients with cirrhosis  [14] ( table 1 ). Indeed, the 
stage of AKI is a predictor of survival in these patients 
 [15] ( fig. 3 ).
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Table 1.  New definitions for the diagnosis and management of AKI in patients with cirrhosis according to [14]
Subject Definition
Definition of AKI Increase in sCr ≥0.3 mg/dl (≥26.5 mmol/l) within 48 h; or a percentage increase sCr ≥50% from baseline 
which is known, or presumed, to have occurred within the prior 7 days
Staging of AKI Stage 1: increase in sCr ≥0.3 mg/dl (26.5 mmol/l) or an increase in sCr ≥1.5–2-fold from baseline
Stage 2: increase in sCr >2–3-fold from baseline
Stage 3: increase of sCr >3-fold from baseline or sCr ≥4.0 mg/dl (353.6 mmol/l) with an acute increase 
≥0.3 mg/dl (26.5 mol/l) or initiation of renal replacement therapy
 Fig. 3. Probability of survival in patients with acute-on-chronic liver failure is affected by AKI. Patients with AKI stages 2–3 exhibit a 
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